Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common heart drug fight staph infections too?

NCT ID NCT06650488

Disease control Sponsor: Todd C. Lee MD MPH FIDSA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

This study looks at whether switching from aspirin to clopidogrel (another blood thinner) can reduce heart complications in people with a serious staph bloodstream infection. About 300 adults already taking aspirin for heart disease will be randomly assigned to stay on aspirin or switch to clopidogrel. The goal is to see if clopidogrel, which may also fight staph bacteria, leads to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clopidogrel
What this could lead to
If it works, this could point toward a better way to prevent heart complications in people with serious staph infections.
What could go wrong
This is a small, early-phase study (Phase 4) with only 300 participants. The drug may not work better than aspirin and could cause bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria: Inclusion Criteria: * Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease) Exclusion Criteria: * Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed) * Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days * Pregnancy * Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month * Allergy to clopidogrel * Concomitant receipt of oral Xa inhibitor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Staphylococcus aureus bloodstream infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial endocarditis staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Staphylococcus aureus bloodstream infection Staphylococcus aureus endocarditis Staphylococcus aureus septicemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

    RECRUITING

    Montreal, Quebec, H4A3S1, Canada

  • NL and Labrador Health Services- Health Sciences Centre

    RECRUITING

    St. John's, Newfoundland and Labrador, NL A1B 3V6, Canada

  • NL and Labrador Health Services- St. Clare's Mercy Hospital

    RECRUITING

    St. John's, Newfoundland and Labrador, NL A1C 5B8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.